Elaris Secures Exclusive Global License from Valneva for C. difficile Vaccine Program

Rhea-AI Summary

Elaris FlexCo secured an exclusive global license from Valneva (Nasdaq: VALN) for antigen technology related to Valneva's C. difficile vaccine candidate VLA84. Elaris will advance a next‑generation vaccine, strengthen its IP position, and pursue IND‑enabling development aiming to start clinical studies around 2027.

The agreement includes customary development, regulatory and commercial milestone payments plus royalties on future net sales, while Elaris plans to add proprietary components to broaden protective immune responses against CDI.

Positive

• Exclusive global license to Valneva's VLA84 antigen technology
• Plan to advance program through IND‑enabling development
• Target to initiate clinical studies around 2027
• Strengthened IP position for Elaris' lead vaccine program

Negative

• Agreement includes development, regulatory and commercial milestone payments
• Royalties on future net sales may reduce future margins
• Clinical start date is a goal (around 2027), not a firm commitment

News Market Reaction – VALN

+1.63%

1 alert

+1.63% News Effect

On the day this news was published, VALN gained 1.63%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual CDI infections (US): 500,000 infections Annual CDI deaths (US): 29,000 deaths Annual CDI infections (Europe): 170,000 infections +1 more

4 metrics

Annual CDI infections (US) 500,000 infections Estimated yearly C. difficile infections in the United States

Annual CDI deaths (US) 29,000 deaths Estimated yearly C. difficile deaths in the United States

Annual CDI infections (Europe) 170,000 infections Estimated yearly healthcare-associated C. difficile infections in Europe

Planned clinical start 2027 Target timing for initiating clinical studies of Elaris’ C. difficile vaccine program

Market Reality Check

Price: $11.19 Vol: Volume 18,024 is slightly...

normal vol

$11.19 Last Close

Volume Volume 18,024 is slightly below 20-day average 20,083 (relative volume 0.9x). normal

Technical Trading above 200-day MA of 8.93 and 10.12% below 52-week high of 12.25, having more than doubled from the 52-week low of 5.4289.

Peers on Argus

VALN is up 4.76% while biotech peers show mixed moves: KURA up 2.68%, AVXL down ...

1 Up 1 Down

VALN is up 4.76% while biotech peers show mixed moves: KURA up 2.68%, AVXL down 2.42%. No broad, same-direction sector move is indicated.

Market Pulse Summary

This announcement highlights Valneva’s strategy of partnering non-core assets while keeping exposure...

Analysis

This announcement highlights Valneva’s strategy of partnering non-core assets while keeping exposure through milestones and royalties. The C. difficile program addresses a sizeable unmet need, with nearly 500,000 infections and about 29,000 deaths annually in the US and more than 170,000 infections in Europe. Investors may watch Elaris’ progress toward planned clinical studies around 2027 alongside Valneva’s other late-stage vaccine catalysts when assessing longer-term impact.

Key Terms

clostridioides difficile, antigen, investigational new drug (ind)

3 terms

clostridioides difficile medical

"Valneva's Clostridioides difficile vaccine candidate, VLA84."

Clostridioides difficile is a bacterium that can overgrow in the gut after antibiotics and cause severe, sometimes recurring, diarrhea and inflammation; it spreads easily in hospitals and care facilities. Investors care because it drives demand for diagnostics, new drugs, vaccines and infection-control services, can raise hospital costs and liability risks, and creates a steady market for companies offering prevention or treatment—like a persistent malfunction that keeps repair business steady.

antigen medical

"Valneva's antigen technology targeting Clostridioides difficile."

A molecule or part of a molecule—often from a virus, bacterium, or abnormal cell—that the immune system recognizes as foreign and reacts to, like a unique fingerprint or smoke detector setting off an alarm. Investors watch antigens because they are the targets for vaccines, diagnostic tests, and certain therapies; changes in how an antigen behaves or is detected can affect product effectiveness, regulatory approval, market demand, and company valuation.

investigational new drug (ind) regulatory

"advance the program through IND-enabling development with the goal of initiating clinical studies"

An investigational new drug (IND) is a drug or biologic that is being tested but has not yet been approved for general use; it is the application and formal status that allows a company to begin human clinical trials under regulator oversight. Investors care because an IND marks the transition from lab work to human testing — like getting a permit to run real-world experiments — which creates important milestones, costs, timelines and regulatory risk that drive a development-stage company's value.

AI-generated analysis. Not financial advice.

VIENNA, Austria, March 18, 2026 /PRNewswire/ -- Elaris FlexCo ("Elaris"), an Austrian biotechnology company developing vaccines against serious bacterial infections, today announced an exclusive global license agreement with Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) for technology related to Valneva's Clostridioides difficile vaccine candidate, VLA84.

Under the agreement, Elaris obtains an exclusive global license to Valneva's antigen technology targeting Clostridioides difficile. Building on this technology, Elaris plans to advance a next-generation vaccine program incorporating additional proprietary components designed to broaden protective immune responses. The agreement strengthens Elaris' intellectual property position and supports advancement of its lead vaccine program.

Elaris plans to advance the program through IND-enabling development with the goal of initiating clinical studies around 2027.

"Securing this license represents an important step toward our goal of preventing serious bacterial infections that disproportionately affect aging and vulnerable populations," said Jason Golan, Chief Executive Officer and Co-Founder of Elaris. "Clostridioides difficile remains a major hospital-acquired infection with high recurrence rates and limited preventive options. By building on Valneva's antigen technology with additional proprietary components, we aim to develop a differentiated vaccine designed to broaden protection against C. difficile infection (CDI)."

CDI is a leading cause of hospital-acquired infections worldwide and represents a significant burden on healthcare systems. In the United States alone, the disease causes nearly 500,000 infections annually and approximately 29,000 deaths, according to the U.S. Centers for Disease Control and Prevention (CDC). In Europe, CDI is estimated to cause more than 170,000 healthcare-associated infections each year. Despite this burden and high recurrence rates following treatment, no prophylactic vaccine is currently approved to prevent CDI.

The agreement includes customary development, regulatory and commercial milestone payments, as well as royalties on future net sales.

"CDI continues to pose a significant public health challenge," said Thomas Lingelbach, Chief Executive Officer of Valneva. "We are pleased to partner with Elaris to advance this technology and look forward to seeing the program progress as Elaris continues development."

About Clostridioides difficile

C. difficile is a toxin-producing bacterium and a leading cause of antibiotic-associated diarrhea and colitis, particularly in hospital and long-term care settings. Infection often occurs following disruption of the gut microbiome caused by antibiotic therapy. Recurrence rates after treatment remain high, and severe cases can lead to life-threatening complications.

About Elaris

Elaris is a biotechnology company developing next-generation bacterial vaccines to protect aging and medically vulnerable populations from serious bacterial diseases. Its lead program is a differentiated vaccine designed to prevent Clostridioides difficile, a severe hospital-acquired infection that primarily affects elderly and immunocompromised patients. By shifting the focus from treatment to prevention, Elaris aims to reduce hospitalizations, antibiotic use, and the growing burden of antimicrobial resistance.

For more information, visit www.elaris.com.

Investor & Media Contact
Jason Golan
Chief Executive Officer
jason.golan@elaris.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/elaris-secures-exclusive-global-license-from-valneva-for-c-difficile-vaccine-program-302717376.html

SOURCE Elaris

FAQ

What did Elaris announce about the C. difficile vaccine license and VALN on March 18, 2026?

Elaris announced an exclusive global license from Valneva for VLA84 antigen technology. According to Elaris, the deal enables a next‑generation vaccine program and advances IND‑enabling development toward clinical studies.

How will the Valneva (VALN) license affect Elaris' vaccine development timeline?

Elaris aims to complete IND‑enabling work and begin clinical studies around 2027. According to Elaris, the license is intended to accelerate development of a broader C. difficile vaccine program.

What financial terms did Elaris disclose for the Valneva (VALN) C. difficile license?

The agreement includes customary development, regulatory and commercial milestone payments plus royalties on future net sales. According to Elaris, no specific payment amounts were disclosed in the announcement.

Does the Elaris license from Valneva (VALN) change Elaris' intellectual property position?

Yes. Elaris said the exclusive license strengthens its intellectual property position for the lead vaccine program. This supports development of additional proprietary components to broaden immune protection.

What clinical benefit does Elaris aim to achieve with the licensed VLA84 technology from VALN?

Elaris plans to build on VLA84 with added proprietary components to broaden protective immune responses against Clostridioides difficile. According to Elaris, the goal is a differentiated prophylactic vaccine for CDI.

What public‑health context did Elaris cite when announcing the VALN license on March 18, 2026?

Elaris highlighted CDI as a major hospital‑acquired infection with high recurrence and no approved prophylactic vaccine. According to Elaris, CDI causes nearly 500,000 U.S. infections and ~29,000 deaths annually per CDC figures.